A detailed history of Capstone Investment Advisors, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Capstone Investment Advisors, LLC holds 12,900 shares of ETNB stock, worth $191,436. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,900
Holding current value
$191,436
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$8.02 - $14.96 $103,458 - $192,984
12,900 New
12,900 $189,000
Q1 2024

May 01, 2024

BUY
$8.13 - $13.77 $843,625 - $1.43 Million
103,767 New
103,767 $1.21 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $690M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Capstone Investment Advisors, LLC Portfolio

Follow Capstone Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.